"" Ralph Moss—Cancer Consultant: 2010

Friday, December 17, 2010

Two nice testimonials

I just received two very nice testimonials from phone consultation clients. I thought I would share them with my blog readers:

"Thank you, Dr Moss, You just made our life a lot less complicated. Since my cancer returned, my wife and I have been researching alternative treatments in this country as well Mexico and Europe. After months of trying to investigate on our own things became confusing and overwhelming. Dr Moss gave us just what we needed. We were very impressed not with just his knowledge of alternative protocols but his insights into many of the cancer clinics around the world was outstanding." --J.D., Dec. 9, 2010.

And here's a second one:

"I've just had my third consultation with Dr. Moss. Not necessarily because anything new has come up but because my doctor recommended a new drug. I feel much better knowing that Dr. Moss has done the research and is able to give me an unbiased opinion as to the safety and efficacy of the drug in question. In addition, his vast knowledge regarding complimentary and alternative medicine, diet and supplements has helped clarify a very confusing and contradictory subject. I would, without reservation, advise any patient who is facing decisions about cancer treatment, to have a consult with Dr. Moss in order to navigate these very murky and many times uncharted waters." --A.M., Dec. 11, 2010.

Thursday, December 16, 2010

FDA Rules Against Avastin

Today, December 16, the US Food and Drug Administration (FDA) took steps to disallow the use of Avastin (bevacizumab) in breast cancer. This overturns the previous director's approval of the drug two years ago--a decision that was medically unwarranted but was worth hundreds of millions of dollars to Roche.

Dr. Richard Pazdur, the FDA's chief of cancer drug review, said, "Given the number of serious and life-threatening side effects, the FDA does not believe there is a favorable risk-to-benefit ratio."

I applaud this decision, as the data behind the use of Avastin in breast cancer was always very shaky. The company, however, is expected to appeal the ruling.

Wednesday, December 15, 2010

Mexican Clinic List

I'm trying to update my knowledge of the Tijuana-area cancer clinics. Below is my current list of 20, including the name of the program, the medical director, the year it was founded, and the Web site (if there is one). I have eliminated a few that have disappeared in the past few years. Do you know of any changes to this list?  Do you have updated information on any of these? I would be interested in hearing about your experiences at these clinics, pro or con. Do you know of any other Mexican clinics that you feel I should investigate? Thanks in advance for your help.

  1. Alivizatos Program at IBC, Rodrigo Rodriguez, MD, 1994, www.alivizatos.com

  2. Alpha Medical Clinic, Humerto Barbosa, MD, 1983, alphamedicalclinic.com

  3. American Metabolic Institute, Geronimo Rubio, MD, 1987, No Web site. Not clear if they are still in business.

  4. Baja NutriCare, Luz Bravo, MD, 2002 No Web site, but see: www.gerson.org

  5. Bio-Medical Center (Hoxsey), Liz Jonas, 1963 No Web site

  6. Center for Holistic Life Extension, Dr. Luis Velazquez, 1989 http://www.extendlife.com/

  7. CHIPSA Immunological Med Ctr., Ron Carreño, MD, 1990 http://chipsa.com/

  8. CIPAG (ex-IMAQ) Isai Castillo, MD, 1984 http://www.drcastillo.com/

  9. Hope4Cancer (Rapha) Clinic Antonio Martinez, MD, 1998 www.hope4cancer.com

  10. Ingles Hospital Sonia Rodriquez, MD, 2002 http://ingles-hospital.com/

  11. IPT clinic Donato P. Garcia, III, MD, 1988, http://iptq.com/

  12. International BioCare Rodrigo Rodriguez, MD, 1975, http://www.biocarehospital.com

  13. Issels Vaccine Program Dr. Mejia, Christian Issels, 1996 http://www.issels.com

  14. Mission Medical Clinic James Gunier, HMD, 1984 http://www.missionmedicalcenter.com

  15. Oasis of Hope Hospital Francisco Contreras, MD 1970 http://www.oasisofhope.com/

  16. Providence Pacifica Hospital Gary Tarasov, MD, Web site unknown

  17. San Diego Clinic Filiberto Muñoz, MD 1998 (But www.sdclinic.com is out of commission)

  18. Sanoviv Hospital M. Wentz PhD, 1998, http://www.sanoviv.com/

  19. Scientific Regeneration Inst. Neil C. Norton, MD 1968 No Web site. But see: www.cancervictors.net

  20. Stella Maris, Clinic Gilberto Alvarez, MD, 1990, http://www.stellamarisclinic.com/

Saturday, December 11, 2010

The Procrustean Bed

[caption id="attachment_145" align="aligncenter" width="300" caption="Herakles killing Procrustes on his bed"][/caption]

Oncologists sometimes try to recruit patients into Phase I (toxicity) clinical trials. But how effective are the experimental treatments provided in such trials? In a recent 2010 study that pooled data from various phase I chemotherapy trials for sarcoma, the partial response rate was 1.6 percent (2 out of 133 subjects) and the complete response (CR) rate was 0.8 percent (1 out of 133). The median progression-free survival was 2.1 months and the median overall survival was 7.6 months. Meanwhile, 18 percent of patients experienced grade 3 or 4 (i.e., critical or life-threatening) toxicity and 12 percent dropped the trial treatment because of toxicity.

Yet here's the amazing part. The authors of this study, at the Royal Marsden Hospital, London, concluded: “Phase I clinical trials could be considered a therapeutic option in sarcoma...due to the low risk of toxicity” (Jones RL, Olmos D, Thway K, et al. Clinical benefit of early phase clinical trial participation for advanced sarcoma patients. Cancer Chemother Pharmacol. 2010. Available at PubMed, emphasis added).

Pardon me for being blunt, but what universe do these scientists inhabit? I wonder if they themselves would submit to such toxic drugs for a less than one percent chance of a "cure" (a "cure" that in any case may last a month or so). And—it seems almost too obvious to ask—how do these scientists define a "low risk of toxicity"? Grade 4 toxicity classically includes such things as massive hemorrhages, life-threatening infection, more than ten episodes of vomiting in a 24 hour period, etc. Even grade 3 toxicity includes such things as "painful erythema, edema or ulcers and (patients) cannot eat" (http://www.rtog.org/members/toxicity/tox.html)

Sometimes I get the impression that various authors reach their conclusions first and then force their data to fit a preconceived notion. The Greeks had a term for this, a "Procrustean bed." This term came from a myth about a highwayman named Procrustes, who physically either cut or stretched the limbs of his victims  to fit the predetermined length of his torture bed. This term has stuck for any situation in which people stretch (or minimize) the data to conform to some preconceived notion.

Sunday, December 5, 2010


[caption id="attachment_133" align="alignnone" width="300" caption="Doctors at Hadassah Hospital, Ein Kerem"][/caption]

This week I am happy to introduce a new special report on "CAM and Cancer in Israel." This report is the result of a trip I took this summer to Israel, touring clinics and meeting doctors who use complementary and alternative medicine in this small but dynamic country. My visit took me to Tel Aviv, Haifa and Jerusalem and their environs. I visited doctors in private practice, in HMOs and in hospitals and university clinics. I also met with inventors and discoverers in this so-called "start up nation." The trip was fascinating on many levels.  CAM is as popular in this small country as any place I have visited and its degree of integration into conventional medicine is arguably the greatest in the world! Although my focus is on what is offered to Israelis there are opportunities here for international cancer patients who want to explore integrative options from some of the finest doctors I know.

"CAM and Cancer in Israel" totals 63 pages in length. It includes photos of the main practitioners, as well as an appendix of contact information (addresses, phone numbers, emails) of these doctors. There is a ten-page bibliography of peer-reviewed journal articles on CAM in Israel and a listing of the major organizations that support CAM usage in this ancient land.

My visit was supported by a grant from a non-profit European foundation, Reliable Cancer Therapies. It was reviewed for accuracy by leading Israeli and American physicians. Some of their comments are given below:

"Ralph Moss's report on CAM and cancer in Israel is extensive and enlightening. I thank him for his significant contribution and support of our activities in the Holy Land."
—Eran Ben-Arye, MD, Haifa, Israel

"Ralph Moss's report provides in-depth research on a subject never investigated before. In the course of his visit he reached most of the serious CAM-cancer practitioners in this country. He has shown that CAM can be practiced in a serious way and add greatly to the treatment of cancer patients."
—Joseph Brenner, MD, Tel Aviv, Israel

"In this report, the story of CAM in Israel is told in a powerful, comprehensive and interesting way by a keen outside observer. I am impressed by Moss's systematic and informative coverage, including relevant background information, a vast number of facts, and a balanced description of a large variety of CAM activities. Moss has done a great job."
—Jacob Shoham, MD, PhD, Ramat-Gan, Israel

"Ralph Moss provides an in-depth report on CAM and cancer in Israel. His detailed encounter with the various experts is an important and much needed guide for both health providers and patients who are interested in this thriving field."
—Isaac Eliaz, MD, Santa Rosa, Calif.

This new Moss report is now available for sale for $19.95 at our Web site, www.cancerdecisions.com. You can order it directly by clicking on the home page banner or by going directly to:

Saturday, November 27, 2010

Is Radiation Therapy A Necessity?

[caption id="attachment_106" align="alignnone" width="241" caption="Does radiation therapy add to survival?"][/caption]

A standard treatment for early-stage breast cancer is to remove the tumor via lumpectomy and then follow that with radiation therapy and the drug, tamoxifen. But a report presented at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO) has called this approach into question. Researchers at Massachusetts General Hospital, Boston, studied women over the age of 70 who had estrogen receptor positive (ER+) tumors that were removed by lumpectomy. The subjects were randomly assigned to receive either tamoxifen alone or tamoxifen plus radiation therapy.

After more than 10 years, the women who received just the tamoxifen fared about the same as those who also received radiation. Although radiation resulted in fewer recurrences in the affected breast, the chance of being free from distant metastases was 95% with tamoxifen alone vs. 93% for tamoxifen plus radiation. The 10-year breast-cancer-specific survival was 98% with tamoxifen alone vs. 96% with radiation. The overall survival was 63% with tamoxifen alone vs. 61% with radiation added, i.e., it was slightly higher when women did not receive radiation.

The authors themselves concluded that “the addition of radiation does not impact survival, distant disease free survival, breast cancer specific survival or breast conservation” (Hughes 2010).

The Web site Breastcancer.org states that “these results shouldn’t be used to make treatment decisions for women younger than 70.” Fair enough. But many readers are bound to wonder whether radiation is worthwhile for women under the age of 70. That wasn’t addressed in this study. Radiation's main purpose after breast surgery is to prevent recurrences, and it does a pretty good job at that. However, its impact on survival is not as great as some people suppose. Even the authoritative Perez and Brady textbook refers to “the lack of survival benefit associated with breast irradiation….” Needless to say, a lot of questions remain about the actual survival benefit of radiation therapy, including some indications for which it is now commonly used.


Hughes KS, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer. 2010 ASCO Annual Meeting. Oral Abstract Session, Breast Cancer - Local-Regional and Adjuvant Therapy. J Clin Oncol 28:15s, 2010 (suppl; abstr 507)

Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N. Engl. J. Med. 2004;351(10):971-977.

Perez, Carlos and Brady, Luther, eds. Principles and Practice of Radiation Oncology, Philadelphia: LWW, 4th ed., 2004, p. 1371.

Saturday, November 20, 2010

Does Dairy Cause or Promote Breast Cancer?

[caption id="attachment_119" align="alignnone" width="200" caption="Does cheese promote breast cancer?"][/caption]

A 1995 prospective study from Norway once showed that a high consumption of whole milk increased the risk of breast cancer: "Consumers of 0.75 litres or more of full-fat milk daily had a relative risk of 2.91 compared with those who consumed 0.15 litres or less" (Gaard 1995).

However, a new study from the Norwegian Women and Cancer contradicts this. The authors looked at the consumption of  specific dairy products, as well as total dairy, in almost 65,000 women between the years 1996 and 2006. During this time, 218 of the premenopausal and 1,189 of the postmenopausal women developed breast cancer. Their conclusion was that "total dairy, adult, and childhood milk consumption was not associated with either pre- or postmenopausal breast cancer risk."

Previous studies also have failed to establish a dairy-breast cancer link. These have included two epidemiological studies (Moorman, 2004 and Parodi 2005), a metaanalysis (Boyd 1993) and a pooled analysis of cohort studies (Missmer 2002). They all concluded that there is no evidence for a strong association between dairy consumption and breast cancer risk.

This is similar to the conclusions of Shin et al. at Harvard that there was  "no association between intake of dairy products and breast cancer in postmenopausal women" (Shin 2002). However, this recent Norwegian study failed to confirm Shin's finding that "among premenopausal women, high intake of low-fat dairy foods, especially skim/low-fat milk, was associated with reduced risk of breast cancer" (ibid.).

Defenders of the low-fat vegan (LFV) diet, such as Prof. T. Colin Campbell, point out that there was no group in this Norwegian study that avoided dairy on principle (Campbell 2010).

In the study's convoluted English, the low dairy consumption group was defined as those participants who had "‘no milk consumption as a child or 1st quartile of dairy consumption as adult and not more than next-lowest consumption (1–3 glasses/day)...." Thus, by my reading, if you did not drink milk as a child but now consumed a limitless amount of dairy, you were still ranked as a low consumer! On the other hand, you are also a low consumer if you drink the equivalent of an 8 oz. glass of milk per day. The low consumer group could therefore contain alot of people who, by vegan standards, would be high consumers. Any difference between such "low consumers" and strict vegans would not show up in this analysis.

While the present study certainly does not support the LFV hypothesis in regard to breast cancer, advocates of that diet do have a point when they object that any beneficial effect of strict dairy avoidance would be unlikely to show up in such a study.


Boyd NF, Martin LJ, Noffel M, Lockwood GA, Trichler DL. A meta-analysis of studies of dietary fat and breast cancer risk. Br J Cancer. 1993;68:627–636.

Campbell TC. Personal communication, Nov. 17, 2010.

Gaard M, Tretli S, Løken EB. Dietary fat and the risk of breast cancer: a prospective study of 25,892 Norwegian women. Int J Cancer. 1995;63(1):13-17.

Hjartåker A, Thoresen M, Engeset D, Lund E. Dairy consumption and calcium intake and risk of breast cancer in a prospective cohort: the Norwegian Women and Cancer study. Cancer Causes Control. 2010;21(11):1875-1885.Moorman PG, Terry PD. Consumption of dairy products and the risk of breast cancer: a review of the literature. Am J Clin Nutr. 2004;80:5–14.

Missmer SA, Smith-Warner SA, Spiegelman D et al. Meat
and dairy food consumption and breast cancer: a pooled analysis
of cohort studies. Int J Epidemiol. 2002;31:78–85.

Parodi PW. Dairy product consumption and the risk of breast cancer. J Am Coll Nutr. 2005;24:556S–568S.

Shin M, Holmes MD, Hankinson SE, et al. Intake of dairy products, calcium, and vitamin d and risk of breast cancer. J. Natl. Cancer Inst. 2002;94(17):1301-1311.

Saturday, November 13, 2010

Does Milk Cause or Promote Prostate Cancer?

[caption id="attachment_100" align="alignnone" width="225" caption="Debate rages over health effects of milk"]Debate rages over health effects of milk[/caption]

Few issues are as contentious as the relationship between milk or dairy products and cancer. There are two vociferous camps claiming, alternately, that milk products are harmful and should therefore generally be avoided, or that dairy (and by extension, other animal-derived foods) are salutary and may actually prevent cancer and other diseases.

Now a new study in the journal The Prostate lends further evidence for the “anti-milk” view. Scientists at the European Institute of Oncology, Milan, and the Université de Montréal, compared 197 prostate cancer (PC) patients with an equal number of men who did not have PC. The participants filled out a food frequency questionnaire, recording their consumption of over 200 food items. There turned out to be a more than twofold increase in the risk of prostate cancer associated with an increased intake of dairy products. At the same time, there was a significant trend toward decreased prostate cancer risk associated in those who reported a higher than average intake of legumes, nuts, both fin- and shellfish and vitamin E (alpha tocopherol).

Interestingly, milk was the only dairy product that was significantly associated with increased prostate cancer risk. Also, the study did not address the issue of grass vs. grain fed cattle, or the problem of pesticide or hormone contamination of milk. But whatever in milk was increasing the PC trend it was not mainly calcium (a theory floated in the past). Calcium showed only a borderline association with PC risk, with only a slightly higher risk with increased calcium consumption.

This study supports the theory that dairy products, and especially standard commercial milk, are involved in the causation of prostate cancer. However, the researchers caution that the mechanisms by which the various nutrients in dairy and in the total diet may interact to influence this risk remain unknown.


Raimondi S, Mabrouk JB, Shatenstein B, Maisonneuve P, Ghadirian P. Diet and prostate cancer risk with specific focus on dairy products and dietary calcium: a case-control study. Prostate. 2010;70(10):1054-1065.

Saturday, November 6, 2010

Israeli Supplement Targets Colon Cancer

[caption id="attachment_89" align="alignnone" width="300" caption="Tel Aviv scientists pioneer food supplement"][/caption]

A new food supplement from Israel targets colon and rectal cancer, as well as ulcerative colitis and other bowel diseases. The product, which has yet to hit the world market, is called Coltect. It is a combination of green tea polyphenols, curcumin powder from the turmeric root and the trace mineral selenium. Its effects were described at a recent oncology meeting and it is the subject of two clinical trials.

Results were presented at the 2010 American Society for Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. The authors, from Tel Aviv Sourasky Medical Center, tried Coltect alone or combined with a common drug, 5-aminosalicylic acid (5-ASA), in cell line and animal models of colon cancer.

Depending on the dose, there was up to an 83 percent inhibition of cancer cell growth using Coltect. In the animal model, the combination of Coltect and the drug 5-ASA reduced the number of precancerous lesions from 66.5 in the control group to 20 in the group that received both agents. The authors concluded that Coltect "can be administered as a chemopreventive regimen to prevent" colorectal cancer.

While waiting for Coltect to hit the world market, one might consider taking a combination of green tea polyphenols, turmeric (with its key ingredient, curcumin) and Brazil nuts (a good source of selenium--use the kind that you have to shell yourself).

As for 5-ASA, it is not available without a prescription. But it is a derivative of salicylic acid and is chemically similar to aspirin. A 2003 journal article concluded: "Preclinical, observational, and clinical data consistently show that non-steroidal anti-inflammatory drugs (NSAIDs)—particularly aspirin—reduce colorectal carcinogenesis" (Hawk and Vine, 2003). So you might ask your doctor about taking a baby aspirin (81 mg) along with the anticancer food components.

Colon cancer afflicts over 100,000 Americans each year. Perhaps some of these cases could be prevented by the judicious use of anticancer foods, supplements and drugs, all of which are readily available. The toxicity of such agents is low and the cost of all together is less than a dollar a day.





Hawk ET, Viner JL. Aspirin: still learning about the wonder drug. Gut. 2003;52(11):1535-1536.

Monday, November 1, 2010

A visit to Colin Campbell

On Friday I drove to Ithaca, NY, to hear a lecture by T. Colin Campbell, PhD, the retired Cornell University professor and author of The China Study. Afterwards we had dinner at his house overlooking Lake Cayuga. I am investigating his theory that a low-fat vegan diet is highly protective against cancer. I am particularly interested in his findings on milk/dairy and cancer incidence. To be sure, I haven't made up my mind on this yet. But I certainly admire the man for his commitment to improving the health of humanity. During his lecture he played a film clip of President Clinton being interviewed recently by Wolf Blitzer of CNN. In it, Clinton pays homage to Campbell and credits him and his colleagues with not only his weight loss but also with greatly improved health. It was impressive.

Saturday, October 30, 2010

Overcoming Side Effects of Tamoxifen

A new study has found that traditional acupuncture can help relieve the adverse side effects of the commonly used drug, tamoxifen. Fifty participants with early breast cancer completed eight traditional acupuncture treatments. Eligible women had been taking tamoxifen for at least six months, and reporting at least four incidents of hot flashes and night sweats per 24 hours for at least three months. Acupuncture reduced the frequency of these unpleasant side effects by half (49.8 percent) in 30 weeks, when the experiment ended. There were beneficial effects as late as 18 weeks after the end of treatment. The women also experienced improvement in fear and anxiety, loss of memory and concentration, menstrual problems, sexual behavior, sleep problems, etc. Dr. Beverly Devalois and her colleagues in Middlesex, UK, concluded that these results compared favorably with other studies on relieving the side effects of tamoxifen. The women “enjoyed improved physical and emotional well-being.” They called for further research.

I would be interested in hearing from readers on what treatments and self-help measures they have found useful in combating the adverse side effects of tamoxifen.

de Valois BA, Young TE, Robinson N, McCourt C, Maher EJ. Using traditional acupuncture for breast cancer-related hot flashes and night sweats. J Altern Complement Med. 2010;16(10):1047-1057.

Saturday, October 23, 2010

Sound Waves Can Kill Cancer

ERRATUM: In a previous version of this blog I stated that only Dr. X. Wang of Guangzhou had published his results using this method. This was incorrect. Dr. Julian Kenyon has also published his results in a paper titled "Activated Cancer Therapy Using Light and Ultrasound...." It appeared in Current Drug Therapy (reference below). You will not find this article in PubMed (which was the source of my error) but it is searchable through another scientific search engine, ingentaconnect.com Dr. Kenyon informs me that he also has another article on the topic due out next year. My apologies to Dr. Kenyon for this omission of his work.


Ultrasound waves can be used to kill cancer cells. The treatment, called sonodynamic therapy, first requires application of a drug called a sonosensitizer, which preferentially accumulates in cancer cells. Physicians can then activate this drug by applying ultrasound and thereby killing the malignancy.

Last month, Japanese scientists announced discovery of a new sonosensitizer, a derivative of Rose Bengal dye. It is said to be ten times more active than ordinary Rose Bengal. But sonodynamic therapy has been around for years. In  2008, I visited mainland China to investigate this treatment and wound up coauthoring a paper on its effects with Dr. X. Wang of Guangzhou. The treatment is also offered at the Dove clinic in England, the Hope4Cancer Institute in Mexico and the Indiana Center for Advanced Medicine in Indianapolis, usually in conjunction with the older technique of photodynamic therapy, which is the use of light and light-activated drugs in cancer.

(Important note: mention of any doctor or clinic in this blog does not constitute an endorsement on my part. It is simply given for informational purposes.)

The costs for this sort of treatment can be considerable. Nonetheless, the field continues to develop, and there are now almost 100 articles in PubMed on this new treatment idea. It is definitely worth keeping an eye on.


Kenyon JN, Fulle RJ, Lewis TJ. Activated cancer therapy using light and ultrasound: A case series of sonodynamic, photodynamic therapy in 115 patients over 4 years. Current Drug Therapy. 2009;4(3): 179-193.

Sugita N, Iwase Y, Yumita N, Ikeda T, Umemura S. Sonodynamically induced cell damage using rose bengal derivative. Anticancer Res. 2010;30(9):3361-3366.

Wang X, Zhang W, Xu Z, Luo Y, Mitchell D, Moss RW. Sonodynamic and photodynamic therapy in advanced breast carcinoma: a report of 3 cases. Integr Cancer Ther. 2009;8(3):283-287.

Saturday, October 16, 2010

Fasting May Improve Chemo

Fasting is prescribed in the Bible and is considered a path to physical and spiritual purity. There are books, articles and Web sites that advocate fasting, some of them even for cancer patients. But many oncologists understandably become alarmed when their patients suggest fasting. After all, cancer is a disease sometimes characterized by unintended weight loss (cachexia). Doctors may feel that fasting will only worsen the situation. But what is the actual science of fasting and its relationship to cancer treatment?

Recently Dr. Valter D. Longo, Fernando M. Safdie and colleagues at the University of Southern California (USC) Andrus Gerontology Center and Department of Biological Sciences, have shown that a 48-hour fast protects normal cells and mice, but not cancer cells, against high-dose chemotherapy.

They also described 10 patients who voluntarily fasted prior to and/or following chemotherapy. None of these reported side effects caused by fasting other than lightheadedness and, of course, hunger. However, most patients reported less fatigue, weakness or gastrointestinal side effects from chemotherapy if they also fasted before and/or after receiving the drugs.

Nor did fasting decrease the effectiveness of the chemotherapy. These USC scientists therefore suggest that fasting, in combination with chemo, is “feasible, safe, and has the potential to ameliorate side effects.” They also recommend consulting one’s physician before undertaking a fast, and I totally agree. There are certainly individuals with cancer who should not fast. But fasting should be feasible for other patients, is cost-free and, at least in this preliminary report, effective at reducing the side effects of chemotherapy.



Thursday, October 14, 2010

Dr. Eliaz Responds to Blog Questions

There have been many comments and questions about the BreastDefend nutritional formula. I therefore asked the developer of the product, Isaac Eliaz, MD, to look at and respond to these. His comprehensive answer can now be found at my blog. The address is http://themossreports.wordpress.com/2010/10/09/dietary-supplement-for-breast-cancer/#comments

Saturday, October 9, 2010

A dietary supplement for breast cancer


[caption id="attachment_46" align="alignnone" width="447" caption="BreastDefend stops proliferation of cancer cells"][/caption]


A paper on a new dietary supplement for breast cancer has appeared this week in the online version of Integrative Cancer Therapies (http://ict.sagepub.com). BreastDefend (BD) is a blend of medicinal mushrooms, herbs and nutritional compounds. In this laboratory study, Indiana University scientists showed that BD inhibited the proliferation and invasiveness of highly metastatic breast cancer cells. Particularly impressive was the effect of the highest dose of BD at 72 hours, where virtually all the cells were suppressed (see illustration).

This isn’t the first time that most of these ingredients have been shown to kill cancer cells. But by combining them in a single formula, one can use lower doses to achieve an synergistic effect. I appreciate the way the developer of the product, Isaac Eliaz, MD of Econugenics, has not just touted his product’s virtues but once again (as with his Pectasol-C) provided scientific proof.

The recommended dose is 1 to 4 capsules, 2 times a day, taken with food, or as directed by one’s health care professional. I have found it for sale on the Internet for as little as $77.99 for 120 capsules. Even at the highest dose this comes to around $5 per day, which seems reasonable for such a promising supplement.

Wednesday, September 22, 2010

A source of hope for cancer patients

There's a fascinating report on so-called spontaneous regressions or remissions of cancer in a British newspaper.


Generally speaking, about half of these regressions follow an infection and/or a high fever. Observation of this phenomenon led to development of the fields of (a) cancer immunology (such as Coley's toxins) and (b) hyperthermia (also called thermotherapy or oncothermia).

It is a source of great hope to cancer patients.

Friday, May 14, 2010

Modified Citrus Pectin Advances

This week brought a major advance in understanding the effects of modified citrus pectin (MCP) on cancer cells. Scientists at Columbia University published a paper showing that MCP stops the growth of prostate cancer (PC) cells in the test tube. Most significantly this effect was seen in both hormone-dependent and hormone-independent forms of the disease. There are very few treatments for hormone- independent PC, and so a report of likely benefit from a simple nutritional agent is highly significant.

Dr. Jun Yan and Dr. Aaron Katz tested two versions of MCP, PectaSol and PectaSol-C, both invented by Dr. Isaac Eliaz. In general, the new form of product outperformed the earlier version. The authors looked at apoptosis (the most prevalent form of programmed cell death) as well as at the inhibition of cell growth. A one percent solution of PectaSol-C was toxic to five cell lines. After four days of treatment, the total destruction of cancer cells ranged from 23.0 to 52.2 percent. The authors concluded that PectaSol and PectaSol-C both inhibited cell proliferation and apoptosis in prostate cancer cell lines.